作者
Peter Ueda, Viktor Wintzell, Elisabeth Dahlqwist, Björn Eliasson, Ann‐Marie Svensson, Stefan Franzén, Soffia Gudbjörnsdottir, Kristian Hveem, Christian Jonasson, Mads Melbye, Anders Hviid, Henrik Svanström, Björn Pasternak
发表日期
2022/3
期刊
Diabetes, Obesity and Metabolism
卷号
24
期号
3
页码范围
473-485
出版商
Blackwell Publishing Ltd
简介
Aim
To assess the comparative cardiovascular and renal effectiveness of sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors versus glucagon‐like peptide‐1 (GLP‐1) receptor agonists in routine clinical practice.
Materials and Methods
A cohort study of nationwide registers from Sweden, Denmark, and Norway, including 87 525 new users of SGLT2 inhibitors and 63 921 new users of GLP‐1 receptor agonists, was conducted using data from 2013‐2018. Co‐primary outcomes, analysed using an intention‐to‐treat exposure definition, were major adverse cardiovascular events (MACE; myocardial infarction, stroke, and cardiovascular death), heart failure (hospitalization or death because of heart failure), and serious renal events (renal replacement therapy, hospitalization for renal events, and death from renal causes).
Results
Use of SGLT2 inhibitors versus GLP‐1 receptor agonists was associated with a …
学术搜索中的文章
P Ueda, V Wintzell, E Dahlqwist, B Eliasson… - Diabetes, Obesity and Metabolism, 2022